Cidel Asset Management Inc. Purchases 109,239 Shares of Haleon PLC Sponsored ADR $HLN

Cidel Asset Management Inc. raised its position in Haleon PLC Sponsored ADR (NYSE:HLN) by 30.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 473,692 shares of the company’s stock after acquiring an additional 109,239 shares during the quarter. Cidel Asset Management Inc.’s holdings in Haleon were worth $4,742,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of HLN. Quotient Wealth Partners LLC lifted its stake in Haleon by 7.9% in the 1st quarter. Quotient Wealth Partners LLC now owns 16,407 shares of the company’s stock valued at $164,000 after purchasing an additional 1,195 shares during the last quarter. Rockefeller Capital Management L.P. increased its position in Haleon by 0.3% during the fourth quarter. Rockefeller Capital Management L.P. now owns 5,397,200 shares of the company’s stock worth $54,566,000 after buying an additional 13,651 shares during the last quarter. Larry Mathis Financial Planning LLC acquired a new position in Haleon during the fourth quarter worth approximately $200,000. Corient Private Wealth LLC raised its stake in Haleon by 8.9% in the fourth quarter. Corient Private Wealth LLC now owns 127,223 shares of the company’s stock valued at $1,263,000 after buying an additional 10,396 shares during the period. Finally, Rehmann Capital Advisory Group raised its stake in Haleon by 136.4% in the fourth quarter. Rehmann Capital Advisory Group now owns 31,183 shares of the company’s stock valued at $315,000 after buying an additional 17,991 shares during the period. Institutional investors own 6.67% of the company’s stock.

Haleon Trading Up 2.3%

Shares of NYSE:HLN opened at $8.97 on Wednesday. Haleon PLC Sponsored ADR has a 12-month low of $8.65 and a 12-month high of $11.28. The stock has a market cap of $39.68 billion, a PE ratio of 23.00, a P/E/G ratio of 2.02 and a beta of 0.13. The business has a 50 day moving average of $9.21 and a 200-day moving average of $9.87. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47.

Haleon (NYSE:HLN) last posted its earnings results on Saturday, February 14th. The company reported $6.32 EPS for the quarter. The firm had revenue of $3.65 billion during the quarter. As a group, equities research analysts forecast that Haleon PLC Sponsored ADR will post 0.55 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on HLN shares. Wall Street Zen upgraded Haleon from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Haleon in a research note on Thursday, April 30th. Argus raised Haleon to a “strong-buy” rating in a report on Tuesday, March 17th. Finally, Rothschild & Co Redburn cut shares of Haleon from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 16th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.